TAPERANK
Open the app
MOVER · THU OCT 1 2026

Why NKTR fell 20.2% on Oct 1 2026: phase 2b data

NKTR-20.2%on Thu Oct 1 2026

Nektar Therapeutics was down 20.2% on the day at $48.33, ranked #1 on 37.2× its usual five-minute volume, when TapeRank recorded this drop at 10:01 ET during regular hours.

THE DAY ON THE LIST · 1 EVENT

  1. 10:01 ET
    MOVER · REGULAR

    $48.33 · ▼ 20.2% ON THE DAY · 37.2× 5M RVOL · RANK #1

    JUSTIFIEDCONFIDENCE3/5

    NKTR is down 15.4% with an additional 5.22% five-minute drop on newly presented Phase 2b rezpegaldesleukin data. The supplied reports do not detail the results, but the same-day clinical-data disclosure is a concrete catalyst consistent with a sharp repricing and heavy volume.

    WHYA 15.4% decline is large, but a fresh Phase 2b clinical-data presentation can plausibly support a move of this magnitude, especially with 23.0x typical volume.
    ANALYZED 09:51 ET · 10 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 10:01 ET
    LAST48.33
    DAY▼ 20.2%
    5 MIN▼ 5.12%
    5M RVOL37.2×
    5M $VOL$9.1M
    FLOAT*34.1M
    RANK#1
    SESSIONREGULAR
    VWAP53.87
    HOD63.49
    LOD48.55
    OR HIGH56.69
    OR LOW54.01
    PREV CLOSE60.55
    PM HIGH63.49
    PM LOW54.64
    GAP▼ 8.49%

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

THE SESSION

  • 09:30 ETOpened at $55.41, -8.5% on the previous close of $60.55
  • 09:30 ETRegular-session high, $56.69
  • 15:48 ETRegular-session low, $46.29
  • 15:59 ETLast trade of the regular session, $47.00, -22.4% on the previous close of $60.55
  • Volume: 5.6M shares in regular hours, 274K before the open

NKTR opened at $55.41 after closing at $60.55 and briefly reached $56.69, but then fell sharply during the session, with TapeRank recording it as the top mover at $48.33 by 10:01 ET. It continued lower to a $46.29 low at 15:48 ET before ending at $47.00, with no halts. TapeRank’s read tied the decline to Nektar’s presentation of Phase 2b rezpegaldesleukin data from the REZOLVE-A and REZOLVE-AD trials, calling the catalyst justified with 3/5 confidence.

WRITTEN THU OCT 15 2026 17:59 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list